Abstract: An ophthalmic device for slowing, inhibiting or preventing myopia progression which is a polymerization product of a monomeric mixture comprising (a) greater than 50 wt. %, based on the total weight of the monomeric mixture, of one or more non-silicone-containing hydrophilic monomers; (b) one or more crosslinking agents; and (c) one or more red-light blocking compounds blocking greater than 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nm to about 800 nm, wherein the one or more red-light blocking compounds have one or more ethylenically unsaturated reactive end groups.

Abstract: A grafted glycosaminoglycan polymer is disclosed. The grafted glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone.

Abstract: A grafted glycosaminoglycan polymer is disclosed. The grafted glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone.

Abstract: A multifunctional crosslinking agent includes one or more repeating units of a siloxanyl group or a silyl-alkyl-siloxanyl group, and at least two ethylenically unsaturated reactive end groups. One of the at least two ethylenically unsaturated reactive end groups is a (meth)acrylate-containing reactive end group or an acrylamide-containing reactive end group and the other one is an allyl-containing reactive end group or a vinyl-containing reactive end group.

Abstract: A method for preparing an ophthalmic device for slowing, inhibiting or preventing myopia progression involves (a) soaking an ophthalmic device in one or more first solvent solutions to swell the ophthalmic device; (b) soaking the swelled ophthalmic device in one or more second solvents solutions comprising one or more red-light blocking compounds blocking greater than about 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nanometers (nm) to about 800 nm to de-swell the swelled ophthalmic device and entrap the one or more red-light blocking compounds in the de-swelled ophthalmic device; and (c) sterilizing the de-swelled ophthalmic device.

Abstract: A method for preparing an ophthalmic device for slowing, inhibiting or preventing myopia progression involves contacting an ophthalmic device having one or more reactive functional groups with one or more red-light blocking compounds having one or more reactive functional groups complementary to the one or more reactive functional groups of the ophthalmic device in a basic solution for a time period sufficient to covalently bond at least one reactive functional group of the ophthalmic device with at least one reactive functional group of the one or more red-light blocking compounds. The one or more red-light blocking compounds block greater than about 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nanometers (nm) to about 800 nm.

Abstract: An ophthalmic device for slowing, inhibiting or preventing myopia progression which is a polymerization product of a monomeric mixture comprising (a) greater than 50 wt. %, based on the total weight of the monomeric mixture, of one or more non-silicone-containing hydrophilic monomers; (b) one or more crosslinking agents; and (c) one or more red-light blocking compounds blocking greater than 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nm to about 800 nm, wherein the one or more red-light blocking compounds have one or more ethylenically unsaturated reactive end groups.

Abstract: A packaging system for the storage of an ophthalmic device is disclosed. The packaging system includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution that includes ectoine or an ophthalmologically acceptable ectoine derivative. The aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is sterilized.

Abstract: A grafted glycosaminoglycan polymer is disclosed. The grafted glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone.